Compounds with 5-ht2 and 5-ht1a agonist activity for treating glaucoma
OwnerRobert J Collier JR., Thomas R Dean +1inventors
InventorsRobert J Collier JR., Thomas R Dean, Mark R Hellberg
Life of this patent
Estimating the term…
Abstract
Compounds with both 5-HT2 and 5-HT1A agonist activity which are useful for lowering and controlling IOP and the treatment of glaucomatous optic neuropathy.
Claims14
A method for lowering and controlling IOP and treating glaucomatous optic neuropathy which comprises administering a pharmaceutically effective amount of a compound with both 5-HT2 and 5-HT1A agonist activity.
A composition for lowering and controlling IOP and treating glaucomatous optic neuropathy comprising a pharmaceutically effective amount of a compound with both 5-HT2 and 5-HT1A agonist activity.
The use of a compound with both 5-HT2 and 5-HT1A agonist activity for the manufacture of a medicament useful for lowering and controlling IOP and treating glaucomatous optic neuropathy.
Dependencies are inferred from the claim text.